Nugent D J, Bray G L, Counts R B, Clements M J, Thompson A R
Br J Haematol. 1986 Nov;64(3):493-502. doi: 10.1111/j.1365-2141.1986.tb02205.x.
Twenty-one patients, 14 with haemophilia A and seven with haemophilia B, completed a double-blind crossover study to evaluate the effects of danazol on factor VIII and factor IX levels. Clotting and immunoradiometric assays were used to measure factor levels at baseline, 2 weeks and 8 weeks on both danazol and placebo. Fibrinogen, plasminogen and activated partial thromboplastin time were measured on all patients during placebo and danazol treatment. Although plasminogen levels rose significantly (P less than 0.01) and fibrinogen decreased (P less than 0.01), factor VIII and IX levels did not change. While on danazol, three patients had increased bleeding and shortened euglobulin lysis times compared to their baseline levels. We conclude that danazol does not raise factor VIII or IX levels and increases bleeding in some patients.
21名患者，其中14名患有甲型血友病，7名患有乙型血友病，完成了一项双盲交叉研究，以评估达那唑对凝血因子VIII和凝血因子IX水平的影响。在达那唑和安慰剂治疗的基线、2周和8周时，使用凝血和免疫放射分析来测量因子水平。在安慰剂和达那唑治疗期间，对所有患者测量纤维蛋白原、纤溶酶原和活化部分凝血活酶时间。尽管纤溶酶原水平显著升高（P<0.01）且纤维蛋白原降低（P<0.01），但凝血因子VIII和IX水平并未改变。在服用达那唑期间，与基线水平相比，三名患者出血增加且优球蛋白溶解时间缩短。我们得出结论，达那唑不会提高凝血因子VIII或IX水平，且会增加部分患者的出血情况。
